NCT02182375View on ClinicalTrials.gov

Effect of BI 201335 Mediated UGT1A1 (Uridine-diphosphate-glucuronosyltransferases) Inhibition in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

March 31, 2010

Conditions
Healthy
Interventions
DRUG

BI 201335 NA

DRUG

Raltegravir

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY